Sign In
Buy NMRA
$1.74
-0.0100 (-0.571%)
At Close: Jun 03, 2026
Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
11:50am, Tuesday, 12'th Nov 2024
Neumora Therapeutics, Inc. (NASDAQ:NMRA ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Helen Rubinstein – Vice President of Investor Relations Henry Gosebruch �
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07:00am, Tuesday, 12'th Nov 2024
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025
Neumora Therapeutics to Participate in Upcoming Conferences in November
07:00am, Wednesday, 06'th Nov 2024
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
07:00am, Wednesday, 14'th Aug 2024
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer's Disease Agitation
07:00am, Thursday, 20'th Jun 2024
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
07:00am, Tuesday, 14'th May 2024
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
01:54pm, Tuesday, 07'th May 2024
Neumora Therapeutics (NASDAQ: NMRA ) just reported results for the first quarter of 2024. Neumora Therapeutics reported earnings per share of -34 cents.
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
07:00am, Tuesday, 07'th May 2024
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024
Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug
12:31pm, Tuesday, 16'th Apr 2024
The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
08:45am, Monday, 15'th Apr 2024
Neumora Therapeutics (NASDAQ: NMRA ) stock is falling on Monday after the clinical-stage biopharmaceutical company announced a clinical hold on a Phase 1 trial of NMRA-266. The Food and Drug Administ
Neumora's early-stage schizophrenia drug study put on hold
07:13am, Monday, 15'th Apr 2024
Neumora Therapeutics said on Monday the U.S. Food and Drug Administration (FDA) had placed a clinical hold on early-stage study of its experimental schizophrenia drug, sending its shares down more tha
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
06:30am, Monday, 15'th Apr 2024
WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and
Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days
07:00am, Wednesday, 13'th Mar 2024
WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced tha
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Thursday, 07'th Mar 2024
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
07:00am, Monday, 22'nd Jan 2024
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the
